不可切除局部晚期或转移性胰腺癌一线化疗方案的比较:系统综述与贝叶斯网络Meta分析
该系统综述与贝叶斯网络Meta分析纳入79项随机对照试验(22 168例患者),比较不可切除局部晚期或转移性胰腺导管腺癌一线化疗的疗效与毒性。以吉西他滨为参照,无进展生存期和总生存期获益最高的方案包括NALIRIFOX、FOLFIRINOX、PAXG及吉西他滨联合白蛋白紫杉醇交替FOLFOX等,证据确定性为低。作者认为可耐受者首选NALIRIFOX和FOLFIRINOX,吉西他滨联合白蛋白紫杉醇为可行替代。
要点
- 共纳入79项随机对照试验、22 168例患者,吉西他滨为最常见对照(50/79项,63%)及参照治疗。
- 无进展生存期获益最高为吉西他滨联合白蛋白紫杉醇交替FOLFOX(HR 0.32)、PAXG(HR 0.35)、NALIRIFOX(HR 0.43)。
- 总生存期获益最高为PAXG(HR 0.40)、吉西他滨联合白蛋白紫杉醇交替FOLFOX(HR 0.46)、NALIRIFOX(HR 0.56)。
核心结论
- 作者认为,能耐受相应方案的患者应首选NALIRIFOX和FOLFIRINOX,吉西他滨联合白蛋白紫杉醇仍是可行替代,尤其在不适合三药联合的患者中。
- 作者提出,有必要开展评估同步或序贯四药联合方案的3期随机对照试验。
研究设计与样本
- 系统综述与贝叶斯网络Meta分析,检索PubMed、Cochrane Central Register of Controlled Trials、Embase及肿瘤学会议网站,截至2023年11月15日。
- 纳入2000年1月1日后发表的2-3期随机对照试验,评估既往未治疗、不可切除局部晚期或转移性胰腺导管腺癌的一线治疗。
- 共筛选6050条记录,最终纳入79项随机对照试验、22 168例患者;主要终点为无进展生存期和总生存期。
- 采用偏差信息准则选择随机效应或固定效应模型,以贝叶斯方法估计HR及95%可信区间;偏倚风险用Cochrane RoB 2工具评估,证据质量采用GRADE方法评价。
- 该研究已在PROSPERO注册,注册号CRD42023450330。
主要发现
- 无进展生存期分析纳入71项试验、19 479例患者,采用固定效应模型;获益最高的方案为吉西他滨联合白蛋白紫杉醇交替FOLFOX(HR 0.32,95%可信区间0.22-0.47)、PAXG(HR 0.35,95%可信区间0.22-0.55)、NALIRIFOX(HR 0.43,95%可信区间0.34-0.54),其后为FOLFIRINOX(HR 0.55,95%可信区间0.47-0.65)和吉西他滨联合白蛋白紫杉醇(HR 0.62,95%可信区间0.54-0.72)。
- 总生存期分析纳入79项试验、22 104例患者,结果与无进展生存期相似;获益最高的方案为PAXG(HR 0.40,95%可信区间0.25-0.65)、吉西他滨联合白蛋白紫杉醇交替FOLFOX(HR 0.46,95%可信区间0.32-0.66)、NALIRIFOX(HR 0.56,95%可信区间0.45-0.70),其后为FOLFIRINOX(HR 0.66,95%可信区间0.56-0.78)和吉西他滨联合白蛋白紫杉醇(HR 0.67,95%可信区间0.59-0.77)。
- 总体偏倚风险为低至一些担忧,证据确定性为低。
临床怎么用
- 作者认为,能耐受相应方案的患者应首选NALIRIFOX和FOLFIRINOX。
- 作者认为,吉西他滨联合白蛋白紫杉醇仍是可行替代方案,尤其在不适合三药联合的患者中。
- 作者提出,有必要开展评估同步或序贯四药联合方案的3期随机对照试验。
局限性
- 证据确定性为低。
- 总体偏倚风险为低至一些担忧。
- 作者提出,有必要开展评估同步或序贯四药联合方案的3期随机对照试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In advanced pancreatic ductal adenocarcinoma (PDAC), first-line chemotherapy is the standard of care. Due to the absence of head-to-head comparisons in clinical trials, we performed this systematic review and network meta-analysis to compare treatment options for PDAC in terms of their efficacy and toxicity. METHODS: PubMed, the Cochrane Central Register of Controlled Trials, Embase, and oncological meetings websites were searched until Nov 15, 2023. We included phase 2-3 randomised controlled trials published after Jan 1, 2000, evaluating first-line treatments in patients with previously untreated, unresectable, locally advanced or metastatic PDAC. Primary endpoints assessed were progression-free survival and overall survival. Summary data were extracted from published reports. The deviance information criterion was used to choose between a random-effects or fixed-effects model. Hazard ratios (HRs) with 95% credible intervals were estimated using a Bayesian approach. The risk of bias was evaluated using the Cochrane Risk of Bias 2 (RoB 2) tool and studies were graded as low, some concerns, or high risk of bias. The quality of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation approach. This systematic review and network meta-analysis is registered with PROSPERO, CRD42023450330. FINDINGS: 6050 records were screened and 79 randomised controlled trials (22 168 patients) were included in the analysis. Gemcitabine was the most frequent comparator (in 50 [63%] of 79 trials) and was considered as the reference treatment. A fixed-effect model was used to analyse the primary outcomes. Regarding progression-free survival (71 trials, 19 479 patients), the most effective treatments were gemcitabine plus nab-paclitaxel alternating folinic acid, fluorouracil, and oxaliplatin ([FOLFOX] HR 0·32, 95% credible interval 0·22-0·47), cisplatin, nab-paclitaxel, capecitabine, and gemcitabine ([PAXG] 0·35, 0·22-0·55), and liposomal irinotecan in combination with fluorouracil, leucovorin, and oxaliplatin ([NALIRIFOX] 0·43, 0·34-0·54), followed by fluorouracil, leucovorin, irinotecan, and oxaliplatin ([FOLFIRINOX] 0·55, 0·47-0·65) and gemcitabine plus nab-paclitaxel (0·62, 0·54-0·72). Similar results were observed for overall survival (79 trials, 22 104 patients): PAXG (HR 0·40, 95% credible interval 0·25-0·65), gemcitabine plus nab-paclitaxel alternating FOLFOX (0·46, 0·32-0·66), and NALIRIFOX (0·56, 0·45-0·70) had the highest benefit, followed by FOLFIRINOX (0·66, 0·56-0·78) and gemcitabine plus nab-paclitaxel (0·67, 0·59-0·77). The overall risk of bias was low to some concerns. Certainty of evidence was low. INTERPRETATION: Our findings suggest that NALIRIFOX and FOLFIRINOX should be the preferred options for patients who can tolerate these regimens, with gemcitabine plus nab-paclitaxel remaining a viable alternative, particularly in patients unfit for triplet therapy. Phase 3 randomised controlled trials investigating concomitant or sequential quadruplets are warranted. FUNDING: None.
引用
- Mastrantoni L, Chiaravalli M, Spring A, et al. Comparison of first-line chemotherapy regimens in unresectable locally advanced or metastatic pancreatic cancer: a systematic review and Bayesian network meta-analysis. Lancet Oncol. 2024. PMID: 39542008. doi:10.1016/S1470-2045(24)00511-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。